X'e bağlı agamaglobulinemi hastalarında uygulanan COVID-19 tedavi prosedürleri

Amaç: COVID-19 pandemisi 2019 yılında başlayan ve birçok kişinin ölümüne neden olan küresel bir salgındır. X'e bağlı agamaglobulinemi (XLA) B hücrelerinin oluşumunu engelleyen genetik bir hastalıktır. İmmünoglobülin replasmanı ile ömür boyu tedavi gerektirir. Bu bireylerde olgun B hücrelerinin olmamasının COVID-19 seyrini olumsuz yönde etkileyebileceği düşünülmektedir. Toplumdaki bazı bireylerde olduğu gibi bu bireylerde COVID-19 enfeksiyonunu hafif atlatanlar görülmüştür. Bu çalışmada PCR ile COVID-19 tanısı konulan XLA hastalarının COVID-19 süreçleri ve bu hastalara uygulanan tedaviler ele alınmıştır.

Anahtar Kelimeler:

Bruton agamaglobulinemisi, Konvelasan plazma, X'e bağlı agamaglobulinemi, COVID-19, SARS-CoV-2

COVID-19 treatment procedures applied to patients with X-linked agammaglobulinemia

Background: COVID-19 is a pandemic that started in 2019 and caused the death of many people. X-linked agammaglobulinemia (XLA) is a genetic disease that prevents the formation of B cells. This disease requires lifelong treatment with immunoglobulin replacement. It is thought that the absence of mature B cells in these individuals may adversely affect the course of the disease. As in some individuals in the society, it was seen that these individuals survived the disease mildly. In this study, the COVID-19 processes of XLA patients who were diagnosed with PCR and the treatments applied to these patients were discussed.

Keywords:

X-Linked agammaglobulinemia, Bruton agammaglobulinemia, COVID-19, SARS-CoV-2, Convalescent plasma,

PDF

___

Almontasheri, A., Al-Husayni, F., Alsuraihi, A.K., Binyahib, H. & Albanna, A. S. (2021). The Clinical course of COVID-19 pneumonia in a 19-year-old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia. Am J Case Rep., 22, e929447. https://doi.org/10.12659/AJCR.929447
Atmar, R.L. & Finch, N. (2022). New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir/ritonavir for treatment of COVID-19. Antimicrobial Agents and Chemotherapy, e02404-02421. Buckland, M.S., Galloway, J.B., Fhogartaigh, C.N., Meredith, L., Provine, N.M., Bloor, S., Ogbe, A., Zelek, W.M., Smielewska, A., Yakovleva, A., Mann, T., Bergamaschi, L., Turner, L., Mescia, F., Toonen, E. J.M., Hackstein, C.P., Akther, H.D., Vieira, V.A., Ceron-Gutierrez, L., . . . & Thaventhiran, J.E.D. (2020). Treatment of COVID-19 with remdesivir in the absence of humoral immunity:a case report. Nat Commun., 11(1), 6385. https://doi.org/10.1038/s41467-020-19761-2
Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C. & Di Napoli, R. (2022). Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet].
Ciuffreda, L., Lorenzo-Salazar, J.M., Alcoba-Florez, J., Rodriguez-Perez, H., Gil-Campesino, H., Inigo-Campos, A., Garcia-Martinez de Artola, D., Valenzuela-Fernandez, A., Hayek-Peraza, M., Rojo-Alba, S., Alvarez-Arguelles, M.E., Diez-Gil, O., Gonzalez-Montelongo, R. & Flores, C. (2021). Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia. Journal of Infection, 83(5), 607-635., https://doi.org/10.1016/j.jinf.2021.07.028
Devassikutty, F.M., Jain, A., Edavazhippurath, A., Joseph, M.C., Peedikayil, M.M.T., Scaria, V., Sandhya, P. & Govindaraj, G.M. (2021). X-Linked agammaglobulinemia and COVID-19: two case reports and review of literature. Pediatr Allergy
Immunol Pulmonol, 34(3), 115-118. https://doi.org/10.1089/ped.2021.0002
Guetl, K., Moazedi-Fuerst, F., Rosskopf, K., Brodmann, M., Krause, R., Eller, P., Wilhelmer, P., Eisner, F., Sareban, N., Schlenke, P., Kessler, H.H., Steinmetz, I., Redlberger-Fritz, M., Stiasny, K. & Stradner, M. (2021). SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia. J Infect., 82(3), 414-451. https://doi.org/10.1016/j.jinf.2020.10.025
Hovey, J. G., Tolbert, D. & Howell, D. (2020). Burton's Agammaglobulinemia and COVID-19. Cureus, 12(11), e11701. https://doi.org/10.7759/cureus.11701
Iaboni, A., Wong, N. & Betschel, S.D. (2021). A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma. J Clin Immunol, 41(5), 923-925. https://doi.org/10.1007/s10875-021-00983-y
Jin, H., Reed, J.C., Liu, S.T.H., Ho, H.E., Lopes, J.P., Ramsey, N.B., Waqar, O., Rahman, F., Aberg, J.A., Bouvier, N.M., Cunningham-Rundles, C. & Mount Sinai Health System Convalescent Plasma, T. (2020). Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract., 8(10), 3594-3596 e3593. https://doi.org/10.1016/j.jaip.2020.08.059
Lackey, A.E. & Ahmad, F. (2021). X-linked Agammaglobulinemia. In Statpearls. StatPearls Publishing [internet].
Loh, S.Y., Bassett, J., Hoodless, E.J. & Walshaw, M. (2021). Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia. BMJ Case Rep., 14(3), e240765. https://doi.org/10.1136/bcr-2020-240765
Milosevic, I., Jovanovic, J. & Stevanovic, O. (2020). Atypical course of COVID-19 in patient with bruton agammaglobulinemia. J Infect Dev Ctries, 14(11), 1248-1251. https://doi.org/10.3855/jidc.13840
Mira, E., Yarce, O.A., Ortega, C., Fernandez, S., Pascual, N.M., Gomez, C., Alvarez, M.A., Molina, I. J., Lama, R. & Santamaria, M. (2020). Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract., 8(8), 2793-2795. https://doi.org/10.1016/j.jaip.2020.06.046
Nguyen, H., Salkeld, J., Agarwal, S. & Goodman, A. (2021). Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. Clin Infect Pract., 12, 100089. https://doi.org/10.1016/j.clinpr.2021.100089
Palomba, E., Carrabba, M., Zuglian, G., Alagna, L., Saltini, P., Fortina, V., Hu, C., Bandera, A., Fabio, G., Gori, A. & Muscatello, A. (2021). Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia. Int J Infect Dis., 110, 338-340. https://doi.org/10.1016/j.ijid.2021.07.064
Pereira, N.M.D., Heath, P.T., Doerholt, K., Almario-Hernandez, A.F., Gilmour, C. & Drysdale, S.B. (2021). SARS-CoV-2 infection in an adolescent with X-linked agammaglobulinemia. Pediatr Infect Dis J., https://doi.org/10.1097/INF.0000000000003360
Soresina, A., Moratto, D., Chiarini, M., Paolillo, C., Baresi, G., Foca, E., Bezzi, M., Baronio, B., Giacomelli, M. & Badolato, R. (2020). Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol., 31(5), 565-569. https://doi.org/10.1111/pai.13263
Speletas, M., Raftopoulou, S., Farmaki, E., Gatselis, N., Germanidis, G., Mouchtouri, V., Hatzianastasiou, S., Georgiadou, S., Tsinti, G., Tsachouridou, O., Tseroni, M., Metallidis, S., Dalekos, G., Eibel, H. & Hadjichristodoulou, C. (2021). B cells and COVID-19: Lessons from agammaglobulinemia patients and the study of functional B cell polymorphisms. J Investig Allergol Clin Immunol., 32(1). https://doi.org/10.18176/jiaci.0726.
Uysal, P.İ. & Yalçın, B. (2018). İntravenöz immünglobulinlerin özellikleri ve uygulamada dikkat edilecek hususlar. Turkiye Klinikleri J Dermatol-Special Topics, 11(2),61-7.
Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., Zhou, X., Wu, Q., Zhang, X. & Feng, Z. (2022). Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Annals of Medicine, 54(1), 516-523.